DRY POWDER INHALER; SPECIAL EMPHASIS TO FORMULATION, DEVICES, CHARACTERIZATION & PROCESS VALIDATION PROTOCOL: A REVIEW

  • Diwaker Dadrwal Sanjivani College of Pharmaceutical Sciences, Village-Rajota, Khetri, Dist-Jhunjhunu, Rajasthan, India

Abstract

The therapy was carried out by inhalation of medicinal plants to cure illness of respiratory tract by ancient people. A wide range of dry powder inhaler devices are presently available on the market to convey drugs into lungs with a view to capitalize on drug delivery with low variability. Drug powder inhalers also face copious clinical challenges, particularly related to capricious patient factors such as age, clinical condition and inspiratory flow. Due to the drug formulation and the design of devices, different drug powder inhalers do not demonstrate the same performance and manufacturers are taking an assortment of device design approaches. The characteristics of an ideal drug powder inhaler, current innovations in powder formulation and device design are not unanimously unswerving in terms of dose variability, clinical efficacy, user friendliness and economy. Particle Size of active pharmaceutical ingredient must be present in size range about 1-10 μm which also assurance that the patient gets the same dose every time at dissimilar airflow rate. Drug powder inhaler are formulated using four types of formulation strategies such as; Carrier free, Drug carrier, Drug additive, Drug carrier additive. Lung deposition study is accomplished by ‘Twin Stage Impingner’. The interior breath gadget is vital in accomplishing adequate transference of breathed in medication to lung which fundamentally grouped in view of measurements sort into single-unit and multi-dosage stores.

Keywords: Drug Delivery, Nebulizer, Twinstage Impingner, Respirable particle

 

Downloads

Download data is not yet available.

Author Biography

Diwaker Dadrwal, Sanjivani College of Pharmaceutical Sciences, Village-Rajota, Khetri, Dist-Jhunjhunu, Rajasthan, India

Sanjivani College of Pharmaceutical Sciences, Village-Rajota, Khetri, Dist-Jhunjhunu, Rajasthan, India

 

References

1. Coates M, Chan H-K, Fletcher D, Chiou H. Influence of Mouthpiece Geometry on the Aerosol Delivery Performance of a Dry Powder Inhaler. Pharm Res. 2007; 24(8):1450-1456.
2. Coates MS, Fletcher DF, Chan H-K, Raper JA. Effect of design on the performance of a dry powder inhaler using computational fluid dynamics. Part 1: Grid structure and mouthpiece length. Journal of Pharmaceutical Sciences. 2004; 93(11):2863-2876.
3. Adi S, Tong Z, Chan H-K, Yang R, Yu A. Impact angles as an alternative way to improve aerosolisation of powders for inhalation? European Journal of Pharmaceutical Sciences. 2010; 41(2):320-327.
4. Islam N and Gladki E. Dry Powder Inhalers (DPIs): A review of device reliability and innovation. Int. J. Pharm. 2008; 360:1-11.
5. Swarbrick J, Boylan C. J. Encyclopedia of pharmaceutical technology. New York: Marcel Dekker; Vol .20. 123-126.
6. Coates MS, Chan H-K, Fletcher DF, Raper JA. Effect of design on the performance of a dry powder inhaler using computational fluid dynamics. Part 2: Air inlet size. Journal of Pharmaceutical Sciences. 2009; 95(6):1382-1392.
7. Chan H-K, Young PM, Traini D, Coates M. Dry powder inhalers: challenges and goals for next generation therapies. Pharmaceutical technology erupoe. 2007; 19-24.
8. Oyarzun Ampeuri FA, Brea J, Loza MI, Torres D, Alonso MJ. Chitosan hyaluronic acid nanoparticles loaded with heparin for the treatment of asthma. Int. J. Pharm. 2009; 381(2):122-129.
9. Frijlink HW, de Boer AH. Trends in the technology-driven development of new inhalation devices. Drug Discovery Today: Technologies 2005; 2(1):47-57.
10. Hoppentocht M, Hagedoorn P, Frijlink HW, de Boer AH. Technological and practical challenges of dry powder inhalers and formulations. Advanced Drug Delivery Reviews. 2014; 75:18-31.
11. Young PM, Traini D, Edge S. Advances in pulmonary therapy. In Williams III R.o., Taft D.R., McConville J.T. Advanced drug formulation design to optimize therapeutics outcomes. Informa healthcare. 2008; 72:2-8.
12. Malcolmson RJ, Buckton G, darcy P, Cox RL, RenwichCE, Embleton JK; In byron PR, Dalby RN and Farr SJ. Respiratory Drug Delivery VI, Interpharm press IL.1998, 365.
13. Yadav N and Lohani A. Dry powders inhalers: A review. Indo global journal of pharmaceutical sciences. 2013; 3(2):142-155.
14. Maa YF, Prestrelksi SJ. Biopharmaceutical powders: particle formation and formulation consideration. Current pharm biotech. 2000; 1(282-302):1389-2010.
15. Pandita R, Rana AC, Seth N, Bala R. Process validation of dry powder inhalers: A review, International research journal of pharmacy. 2011; 2(12):114-116.
Statistics
101 Views | 118 Downloads
How to Cite
Dadrwal, D. (2017). DRY POWDER INHALER; SPECIAL EMPHASIS TO FORMULATION, DEVICES, CHARACTERIZATION & PROCESS VALIDATION PROTOCOL: A REVIEW. Journal of Drug Delivery and Therapeutics, 7(3), 50-54. https://doi.org/10.22270/jddt.v7i3.1448